Mitochondrial antiviral-signaling (mavs) polypeptides and detection and use thereof
AssigneeUniversity of Vermont and State Agricultural College
InventorsIwona A. Buskiewicz, Andreas Koenig
Life of this patent
Estimating the term…
Abstract
The invention relates, in part, to compounds, compositions, and methods to assess characteristics of mitochondrial antiviral-signaling (MAVS) polypeptides and also to methods of modulating MAVS polypeptide characteristics. In addition, the invention relates, in part, to assays to assess characteristics of polypeptides.
Claims31
A method of selecting an autoimmune disease treatment for a subject, comprising:
- (a) identifying a subject at risk for an autoimmune disease;
- (b) obtaining a serum sample from the subject;
- (c) contacting the serum sample with a MAVS-binding agent under suitable conditions for the MAVS-binding agent to form a bound complex comprising the MAVS-binding agent and an oligomerized MAVS polypeptide complex,
- (d) determining a characteristic of the bound complex;
- and
- (e) selecting a treatment for the autoimmune disease based at least in part on the determined characteristic of the bound complex.
3-10. (canceled)
12-47. (canceled)
A method of preparing a bound complex comprising a serum mitochondrial antiviral-signaling (MAVS) oligomerized polypeptide complex and a MAVS-binding agent, the method comprising:
- contacting a MAVS-binding agent with a serum sample believed to be at risk of containing an oligomerized MAVS polypeptide complex, wherein the contact is under conditions suitable for the MAV-binding agent to form a bound complex with the oligomerized MAVS polypeptide complex.
(canceled)
(canceled)
57-60. (canceled)
(canceled)
(canceled)
66-84. (canceled)
A method of treating an autoimmune disease in a subject, the method comprising:
- administering to a subject in need of such treatment an effective amount of a modulating compound that inhibits oligomerization of a mitochondrial antiviral-signaling (MAVS) polypeptide to reduce oligomerization of the MAVS polypeptide in the subject.
(canceled)
91-95. (canceled)
98-118. (canceled)
Dependencies are inferred from the claim text.